Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest/Lipha acamprosate

Executive Summary

Alcohol abstinence drug acamprosate deemed "not approvable" by FDA, Forest says July 2. The agency is requesting "at least" one additional U.S. safety and efficacy trial and further pharmacokinetic analyses and pre-clinicals. The NDA was based on three European studies from the late-1980s to mid-1990s and one U.S. trial that did not demonstrate efficacy over placebo (1"The Pink Sheet" May 20, p. 25). Forest and Lipha expect a meeting with FDA in August. The NDA was filed in December 2001 and received a priority review...

You may also be interested in...



Forest/Lipha Acamprosate Subgroup Analysis Of EU Data Suggested By Cmte.

A subgroup analysis of European trial data for Forest/Lipha's acamprosate would help clarify whether trends seen in certain U.S. clinical trial subpopulations are meaningful, FDA's Psychopharmacologic Drugs Advisory Committee suggested May 10

Speculation Over Moderna Vaccine Deal With Tata, Wockhardt

Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.

QUOTED. 27 January 2021. Scott Whitaker.

Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel